Skip to content
Sign in
European CDMOs compared · 2026 census

CDMOs in Switzerland: 14 compared (2026)

14 of the 255 contract development and manufacturing organisations in A4BEE’s European census are headquartered in Switzerland. The largest, with revenue over €1bn, are Lonza, Sandoz and Siegfried. 4 sit between €250m and €1bn and 7 are smaller or niche.

By ownership: 3 family-owned, 3 private equity, 6 listed and 2 part of a pharma or industrial group. The most common capabilities are small-molecule API (9), biologics and biosimilars (5), antibody-drug conjugate (ADC) (4), monoclonal antibody (3) and cell and gene therapy (3). 8 of the 14 rows rest on audited reports or official company disclosures; the rest come from secondary sources or estimates.

Open these 14 in the interactive mapAll 255 European CDMOs

14 companies

CDMOs in Switzerland

CompanyHQOwnershipSizeRevenue (as reported)ModalitiesData
LonzaIntegrated Biologics grew +32.2% CER in 2025; the sector's clear scale + digital leader.BaselListedTier 1CHF 6.5 bn (2025)Biologics and biosimilars, Monoclonal antibody, Antibody-drug conjugate (ADC), Small-molecule API, Cell and gene therapy, Microbial and proteinhigh
SandozBiosimilars leader; CDMO/CMO is a secondary activity to its own portfolio.BaselListedTier 1n/dBiologics and biosimilars, Monoclonal antibodylow
SiegfriedZofingenListedTier 1CHF 1.29 bn (2024)Small-molecule API, Sterile fill-finishlow
BachemSIX-listed peptide & oligonucleotide CDMO; largest independent peptide maker.BubendorfListedTier 2CHF 605.3 m (2024)Peptide, Small-molecule APIhigh
CordenPharmaPeptide + lipid/LNP specialist riding the GLP-1 boom (e.g. Viking deal).BaselPrivate equityTier 2~US$530 mPeptide, mRNA and LNP, Sterile fill-finish, Small-molecule APImedium
Dottikon ES HoldingSIX-listed exclusive-synthesis CDMO specialising in hazardous chemistry, APIs, HPAPIs and intermediates.DottikonListedTier 2CHF 424.3 m (H1 FY25/26)Small-molecule APIhigh
PolyPeptide GroupSIX-listed independent CDMO for peptide & oligonucleotide APIs.BaarListedTier 2~€336 m (2024)Peptidehigh
Acino InternationalBranded-generics pharma that also runs a documented CDMO/contract-manufacturing arm for oral solid dosage forms.ZurichPart of a pharma or industrial groupArcera / ADQTier 3not disclosedOral solid dosemedium
CARBOGEN AMCISDrug-substance & drug-product CDMO (incl. HPAPI/ADC); Swiss arm of Indian-listed Dishman Carbogen Amcis.BubendorfPart of a pharma or industrial groupDishman Carbogen Amcis (India)Tier 3not disclosedSmall-molecule API, Antibody-drug conjugate (ADC)medium
CelonicBaselFamily-ownedJRS GroupTier 3n/dMonoclonal antibody, Biologics and biosimilars, Cell and gene therapymedium
Cerbios-Pharma~50-year-old CDMO for HPAPIs, ADCs, recombinant proteins and live biotherapeutics; acquired by HAS Healthcare 2025.LuganoPrivate equityHAS HealthcareTier 3not disclosedSmall-molecule API, Antibody-drug conjugate (ADC), Biologics and biosimilars, Microbial and proteinhigh
HAS Healthcare Advanced SynthesisEx-Helsinn HPAPI/anticancer API CDMO spun out as independent in 2022; now parent of Cerbios.BiascaFamily-ownedBraglia familyTier 3not disclosedSmall-molecule API, Antibody-drug conjugate (ADC)high
Micro-SphereFounder-led CDMO specialising in spray drying (poorly-soluble drugs) and capsule filling, clinical to commercial.MonteggioFamily-ownedTier 3not disclosedOral solid dose, Small-molecule APIhigh
ten23 healthSterile drug-product formulation & fill-finish CDMO (biologics, cell & gene therapy); absorbed swissfillon (Visp) in 2021.BaselPrivate equity3i GroupTier 3not disclosedSterile fill-finish, Biologics and biosimilars, Cell and gene therapyhigh

Size: Tier 1 (revenue over €1bn) · Tier 2 (€250m–€1bn) · Tier 3 (under €250m or niche).

Revenue, staff and site figures are as reported and mix audited accounts with commercial estimates, which are often wrong for private companies. Each row carries a confidence mark; verify a figure before quoting it.

Browse the census

Other European CDMO lists